The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Sarepta Therapeutics Inc

Nasdaq: SRPT
Last

(U.S.) $36.69

Today's change+0.46 +1.27%
Updated August 28 4:00 PM EDT. Delayed by at least 15 minutes.
 

Sarepta Therapeutics Inc

Nasdaq: SRPT
Last

(U.S.) $36.69

Today's change+0.46 +1.27%
Updated August 28 4:00 PM EDT. Delayed by at least 15 minutes.

Sarepta Therapeutics Inc Hits New 52-week High

Sarepta Therapeutics Inc closed up Friday by (U.S.)$0.46 or 1.27% to (U.S.)$36.69 and setting a new 52-week high. Over the last five days, shares have gained 8.36% and are currently 1.34% off of the 52-week high. Shares have outperformed the S&P 500 by 66.19% during the last year.

Key company metrics

  • Open(U.S.) $36.13
  • Previous close(U.S.) $36.23
  • High(U.S.) $37.19
  • Low(U.S.) $35.62
  • Bid / Ask-- / --
  • YTD % change+153.56%
  • Volume1,689,523
  • Average volume (10-day)1,689,137
  • Average volume (1-month)1,448,975
  • Average volume (3-month)1,259,407
  • 52-week range(U.S.) $11.33 to (U.S.) $37.19
  • Beta0.94
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$4.29
Updated August 28 4:00 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-16,303.13%

Sarepta Therapeutics Inc has a net profit margin of -16,303.13%. Besides being negative, it is also below the industry average and implies that this company is not effective at turning revenues into bottom line profit.
Company Books

S&P TSX0.71%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2015Q1/2015Q4/2014Q3/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014
Revenue0001
Total other revenue--------
Total revenue0001
Gross profit--------
Total cost of revenue--------
Total operating expense42624535
Selling / general / administrative13231413
Research & development29393122
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)----0--
Other operating expenses, total--------
Operating income-42-62-45-34
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-42-62-44-29
Income after tax-42-62-44-29
Income tax, total--------
Net income-42-62-44-29
Total adjustments to net income--------
Net income before extra. items-42-62-44-29
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-42-62-44-29
Inc. avail. to common incl. extra. items-42-62-44-29
Diluted net income-42-62-44-29
Dilution adjustment------0
Diluted weighted average shares41414141
Diluted EPS excluding extraordinary itemsvalue per share-1.01-1.49-1.07-0.71
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-1.01-1.49-1.07-0.71